Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 5, Issue 1, 2003, Pages 57-66

  Ristic, Smiljana ^a   Bates, Peter C ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Cambridge Medical Writing Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

BOLUS INJECTION; CLINICAL TRIAL; DIET; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TIME SERIES ANALYSIS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0037272950     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503763816472     Document Type: Review

References (42)

1. Heinemann L, Starke AAR, Hohmann A, Berger M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res 1992;26(Suppl):137-139.
2. Brange J, Vølund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-335.
3. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR: A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-2057.
4. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
5. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
6. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR, Berger M: Prandial glycaemia after carbohydrate-rich meal in type 2 diabetes patients using the rapid acting insulin analogue Lys(B28), Pro(B29) human insulin. Diabet Med 1996;13:625-629.
7. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Improved mealtime treatment of diabetes mellitus using an insulin analog. Clin Ther 1997;19:62-72.
8. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:1249-1255.
9. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multi-center randomised double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998;21:1904-1909.
10. Avignon A, Radauceanu A, Monnier L: Non-fasting plasma glucose is a better marker of diabetic control then fasting plasma glucose in type 2 patients. Diabetes Care 1997;20:1822-1826.
11. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-286.
12. Pampanelli S, Torlone E, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB: Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care 1995;18:1452-1459.
13. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996;19:945-952.
14. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-588.
15. Amiel S, Home PD, Jacobsen JL, Lindhom A: Insulin aspart is safe for long-term treatment [abstract]. Diabetologia 2001;44(Suppl 1):A209.
16. Del Sindaco P, Ciofetta M, Lalli C, Periello G, Pampanelli S, Torlone E, Brunetti P, Bolli GB: Use of the short-acting insulin analogue lispro in intensive treatment of type I diabetes mellitus: importance of appropriate replacement of basal insulin and timeinterval injection-meal. Diabet Med 1998;15:592-600.
17. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type I diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-477.
18. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B: Improvement of blood glucose control in Type I diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999;16:319-324.
19. Ronnemaa T, Viikari J: Reducing snacks when switching from conventional soluble to lispro insulin treatment: effects on glycaemic control and hypoglycaemia. Diabet Med 1998;15:601-607.
20. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care 1997;20:1287-1289.
21. Jansson P-A, Ebeling P, Smith U: Improved glycemic control can be better maintained with insulin lispro than with human regular insulin. Diab Nutr Metab 1998;11:194-199.
22. Zinman B, Ross S, Campos RV, Strack T: Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. Diabetes Care 1999;22:603-608.
23. Home PD, Lindholm A, Riis A: Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-770.
24. Chase PH, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK: The impact of the Diabetes Control and Complications Trial and Humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24:430-434.
25. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind cross-over study. Diabetes 1997;46:440-443.
26. 1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-982.
27. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999;22:784-788.
28. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F: A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001;15:295-300.
29. Bode B, Steed R, Davidson P: Continuous subcutaneous insulin infusion (CSII): a study comparing lispro to regular human insulin [abstract]. Diabetes 1997;46(Suppl 1):0167.
30. Lins P-E, Johansson U-B, Wredling R, Adamson U: Blood glucose variability and well-being during CSII using insulin lispro and regular insulin [abstract]. Diabetes 1998;47(Suppl 1):0039.
31. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
32. Garg SK, Anderson JH, Gerard LA, Mackenzie TA, Gottlieb PA, Jennings MK, Chase HP: Impact of insulin lispro on HbAlc values in insulin pump users. Diabetes Obes Metab 2000;2:307-311.
33. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J-P: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 2000;23:1232-1235.
34. Tsui E, Barnie A, Ross S, Parkes R, Zinman B: Intensive insulin therapy with insulin lispro. Diabetes Care 2001;24:1722-1727.
35. Del Prato S, Tiengo A: The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001;17:164-174.
36. Feinglos MN, Thacker CH, English J, Bethel MA: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-1543.
37. Bastyr EJ, Johnson ME, Trautmann ME, Anderson JH, Vignati L: Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-1714.
38. Brodows R, Schwartz S, Stuart C: Combination of insulin lispro, metformin, or bedtime NPH with sulfonylurea (SU) following secondary SU failure [abstract]. Diabetes 1999;48(Suppl 1):0450.
39. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SC, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405-412.
40. Epidemiology of Diabetes Interventions and Complications Research Group: Epidemiology of diabetes interventions and complications (EDIC). Diabetes Care 1999;22:99-111.
41. Heller SR, Amiel SA, Mansell P: Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 1999;22:1607-1611.
42. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-C, Avogaro A, Tiengo A, Del Prato S: Restoration of early phase in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.